Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences level 3 contingent consideration liabilities ($M) ($M)
Form 10-Q / 10-K Note 3 Fair Value Measurements
Latest, FY2025
278
Period ended Dec 31, 2025
Change on a year earlier
+35.0%
206 in FY2024
History
7 years
Since FY2014
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Level 3 contingent consideration liabilities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 278 | +35.0% | Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗ |
| FY2024 | Dec 31, 2024 | 206 | -9.6% | Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 228 | -17.1% | Form 10-K (gild-20241231.htm, filed 2025-02-28) ↗ |
| FY2022 | Dec 31, 2022 | 275 | -13.2% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 317 | – | Form 10-K (filed 2023-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2022-02-23) ↗ |
| FY2014 | Dec 31, 2014 | 133 | – | Form 10-Q (filed 2015-05-08) ↗ |
Breakdown
What makes up level 3 contingent consideration liabilities ($m)
Cite this data
StockData. (2026). Gilead Sciences Level 3 contingent consideration liabilities ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/cc_liab_tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.